Previous 10 | Next 10 |
Early clinical data show expansion and persistence of cells and support the efficacy and safety profile of ALVR109 in transplant and non-transplant patients with COVID-19 AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced preclinical an...
Read the full story here: For further details see: Wall Street Breakfast: El Salvador Adopts Bitcoin (Podcast)
AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate update at the Morgan Stanley 19th Annual Global Healthcare Conference on September 14 th at 4:15 p.m. ET. The presentation will be available on the Investors & Press section of...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Reddit targets BitcoinThe Bitcoin (BTC-USD) subreddit community is looking at a coordinated plan to buy the cryptocurrency to commemorate El Salvador's law...
Barron's spoke with investors and an analysts who focus on the biotech field to find names that are poised to make a comeback. Many biotech stocks have had a tough year so far. The SPDR Biotech ETF (NYSEARCA:XBI) is down 4.7% year-to-date. That compares to a 20.8% return in the same period fo...
You can read full article here. Drop here! For further details see: Wall Street Breakfast: The Week Ahead (Podcast)
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead Investors will come back from a three-day weekend with an accelerated schedule of corporate events and major industry co...
Gainers: CARA +24.3%. CLXT +5.9%. ABNB +3.9%. AMTX +3.9%. ACIU +2.4%. Losers: TBPH -24.1%. XERS -3.0%. CPOP -2.7%. MRIN -2.6%. ALVR -2.1%. For further details see: CARA, CLXT, TBPH and XERS among after hours movers
AlloVir (NASDAQ:ALVR): Q2 GAAP EPS of -$0.60 misses by $0.11. Cash, cash equivalents, and marketable securities of $313.3M. Press Release For further details see: AlloVir EPS misses by $0.11
- Posoleucel (Viralym-M, ALVR105) proof-of-concept studies in multi-virus prevention in stem cell transplant patients and BK viremia in kidney transplant patients continue to progress with initial data expected 4Q21 - Posoleucel Phase 3 pivotal trial in virus-associated hemorr...
News, Short Squeeze, Breakout and More Instantly...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...